Most Read Articles
Natalia Reoutova, 2 days ago

A recent study involving 99 patients in Hong Kong demonstrated that arsenic trioxide (As2O3), used as part of induction and maintenance treatment for newly diagnosed acute promyelocytic leukaemia (APL), is safe and highly effective, achieving 100 percent complete response (CR), 3-year leukaemia-free survival (LFS) and 3-year overall survival (OS) rates. 

Podcast: Prof Peter Schmid speaks on PFS benefit with atezolizumab-chemo combo in triple negative breast cancer in IMpassion130

29 Oct 2018
Podcast: Prof Peter Schmid speaks on PFS benefit with atezolizumab-chemo combo in triple negative breast cancer in IMpassion130
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 2 days ago

A recent study involving 99 patients in Hong Kong demonstrated that arsenic trioxide (As2O3), used as part of induction and maintenance treatment for newly diagnosed acute promyelocytic leukaemia (APL), is safe and highly effective, achieving 100 percent complete response (CR), 3-year leukaemia-free survival (LFS) and 3-year overall survival (OS) rates.